[{"indications": "Indications\u00a0locally advanced prostate cancer at high risk of disease progression,\r\neither alone or as adjuvant treatment to prostatectomy or radiotherapy;\r\nlocally advanced, non-metastatic prostate cancer when surgical castration\r\nor other medical intervention inappropriate; advanced prostate cancer\r\nin combination with gonadorelin analogue or surgical castration", "name": "BICALUTAMIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.3 Sex hormones and hormone antagonists in malignant disease", "8.3.4 Hormone antagonists", "8.3.4.2 Gonadorelin analogues and gonadotrophin-releasing hormone antagonists", "Anti-androgens", "BICALUTAMIDE"], "cautions": "Cautions\u00a0consider periodic liver function tests; interactions: Appendix 1 (bicalutamide)", "side-effects": "Side-effects\u00a0nausea, diarrhoea, cholestasis, jaundice; asthenia,\r\nweight gain; gynaecomastia, breast tenderness, hot flushes, impotence,\r\ndecreased libido; anaemia; alopecia, dry skin, hirsutism, pruritus; less commonly vomiting, abdominal pain, dyspepsia, interstitial\r\nlung disease, pulmonary fibrosis, depression, haematuria, thrombocytopenia,\r\nhypersensitivity reactions including angioneurotic oedema and urticaria; rarely cardiovascular disorders (including angina, heart\r\nfailure, and arrhythmias), and hepatic failure", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/31762.htm", "doses": ["Locally advanced prostate cancer at high risk of disease\r\nprogression, 150\u00a0mg once daily", "Locally advanced, non-metastatic prostate cancer when surgical\r\ncastration or other medical intervention inappropriate, 150\u00a0mg once\r\ndaily", "Advanced prostate cancer, in combination with gonadorelin analogue\r\nor surgical castration, 50\u00a0mg once daily (started at the same time\r\nas surgical castration or at least 3 days before gonadorelin therapy,\r\nsee also notes above)"]}]